Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
The eukaryotic translation initiation factor eIF4E is deregulated in many human cancers, and its overexpression in cells leads to malignant transformation. Oncogenic properties of eIF4E are directly linked to its ability to bind 7-methyl guanosine of the 5′ mRNA. Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1. Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro , of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo , and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients. These findings describe a specific, potent, and unforeseen mechanism of action of ribavirin. Quantum mechanical and NMR structural studies offer directions for the development of derivatives with improved cytostatic and antiviral properties. In all, ribavirin's association with eIF4E may provide a pharmacologic means for the interruption of posttranscriptional networks of oncogenes that maintain and enhance neoplasia and malignancy in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Massagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
Prediction of central nervous system embryonal tumour outcome based on gene expression
Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y. H., Goumnerova, L. C., Black, P. M., Lau, C., et al. (2002) · Nature · doi:10.1038/415436a · Cited by 2,371
eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of Translation
Gingras, A.-C., Raught, B., & Sonenberg, N. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.913 · Cited by 2,121
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
RNA virus error catastrophe: Direct molecular test by using ribavirin
Crotty, S., Cameron, C. E., & Andino, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111085598 · Cited by 849
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y. N., Hong, Z., Andino, R., & Cameron, C. E. (2000) · Nature Medicine · doi:10.1038/82191 · Cited by 820
Cocrystal Structure of the Messenger RNA 5′ Cap-Binding Protein (eIF4E) Bound to 7-methyl-GDP
Marcotrigiano, J., Gingras, A.-C., Sonenberg, N., & Burley, S. K. (1997) · Cell · doi:10.1016/s0092-8674(00)80280-9 · Cited by 678
Cited by
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Mechanisms of action of ribavirin against distinct viruses
Graci, J. D., & Cameron, C. E. (2006) · Reviews in Medical Virology · doi:10.1002/rmv.483 · Cited by 549
Cellular IRES-mediated translation: The war of ITAFs in pathophysiological states
Komar, A. A., & Hatzoglou, M. (2011) · Cell Cycle · doi:10.4161/cc.10.2.14472 · Cited by 415
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“[Ribavirin has been reported to behave as a cap analogue ex vivo (165).”
BackgroundTargeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy
Graff, J. R., Konicek, B. W., Carter, J. H., & Marcusson, E. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5635 · Cited by 332
Assouline, S., Culjkovic, B., Cocolakis, E., Rousseau, C., Beslu, N., Amri, A., Caplan, S., Leber, B., Roy, D.-C., Miller, W. H., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205153 · Cited by 314
Self-citationRoles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
Targeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 229
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501019 · Cited by 204
“eIF4E nuclear bodies must be intact in order to act in mRNA export because their disruption is correlated with a loss of export activity (Topisirovic et al., 2003a; Kentsis et al., 2004).”
BackgroundSelf-citationTargeting Eukaryotic Translation Initiation Factor 4E (eIF4E) in Cancer
Hsieh, A. C., & Ruggero, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0433 · Cited by 186
Translation Regulation as a Therapeutic Target in Cancer
Grzmil, M., & Hemmings, B. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0026 · Cited by 103
Metadata
- Authors
- Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L., & Borden, K. L. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-12-15
- Volume
- 101
- Issue
- 52
- Pages
- 18105-18110
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2033489247
- Cited by
- 305
- References
- 46
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.